{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:46:13Z","timestamp":1781541973855,"version":"3.54.5"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.blre.2018.01.001","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T16:25:24Z","timestamp":1517415924000},"page":"265-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?"],"prefix":"10.1016","volume":"32","author":[{"given":"H.C.A.M.","family":"Hazendonk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"van Moort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.A.","family":"Math\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.W.G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.W.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Cnossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2018.01.001_bb0005","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.01.001_bb0010","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0038-1645706","article-title":"The increasing prevalence of haemophilia","volume":"63","author":"Rosendaal","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.01.001_bb0015","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.01.001_bb0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2516.2010.02450.x","article-title":"Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials","volume":"17","author":"Fischer","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jcp.35.3.289","article-title":"Effect of height and weight on the in vivo recovery of transfused factor VIII C","volume":"35","author":"Aronstam","year":"1982","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2018.01.001_bb0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003088-199222050-00005","article-title":"Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies","volume":"22","author":"Bjorkman","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.blre.2018.01.001_bb0035","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2516.1997.00091.x","article-title":"Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A","volume":"3","author":"Carlsson","year":"1997","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0040","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range 3\u201374years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A","volume":"65","author":"Bjorkman","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.blre.2018.01.001_bb0045","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/hae.12216","article-title":"Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy","volume":"19","author":"Bjorkman","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0609.1985.tb00739.x","article-title":"Kinetic evaluation of four Factor VIII concentrates by model-independent methods","volume":"34","author":"Matucci","year":"1985","journal-title":"Scand J Haematol"},{"key":"10.1016\/j.blre.2018.01.001_bb0055","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.01.001_bb0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"Suppl. 77","key":"10.1016\/j.blre.2018.01.001_bb0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/ort.1965.36.suppl-77.01","article-title":"Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B","author":"Ahlberg","year":"1965","journal-title":"Acta Orthop Scand Suppl"},{"key":"10.1016\/j.blre.2018.01.001_bb0070","first-page":"1","year":"2009","journal-title":"Van Zuiden Communications BV"},{"key":"10.1016\/j.blre.2018.01.001_bb0075","series-title":"Guidelines for the management of hemophilia","author":"Srivastava","year":"2012"},{"key":"10.1016\/j.blre.2018.01.001_bb0080","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2010.08139.x","article-title":"A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A","volume":"149","author":"Richards","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.01.001_bb0085","series-title":"Nordic hemophilia guidelines","first-page":"1","author":"Armstrong","year":"2015"},{"key":"10.1016\/j.blre.2018.01.001_bb0090","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A","volume":"7","author":"Collins","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.01.001_bb0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.1981.tb02722.x","article-title":"Calculating the dose of factor VIII in the management of haemophilia","volume":"48","author":"Ingram","year":"1981","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.01.001_bb0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1538-7836.2009.03703.x","article-title":"Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens","volume":"8","author":"Collins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.01.001_bb0105","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jth.12586","article-title":"von Willebrand disease and aging: an evolving phenotype","volume":"12","author":"Sanders","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.01.001_bb0110","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2516.2001.00465.x","article-title":"Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis","volume":"7","author":"Bjorkman","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0115","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2516.2003.00762.x","article-title":"The pharmacokinetics of clotting factor therapy","volume":"9","author":"Berntorp","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0120","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1182\/blood.V92.11.3983","article-title":"The life cycle of coagulation factor VIII in view of its structure and function","volume":"92","author":"Lenting","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.01.001_bb0125","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1538-7836.2007.02572.x","article-title":"Clearance mechanisms of von Willebrand factor and factor VIII","volume":"5","author":"Lenting","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.01.001_bb0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00194400","article-title":"Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation","volume":"46","author":"Bjorkman","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.blre.2018.01.001_bb0135","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/0006-291X(83)90365-0","article-title":"Binding of coagulation factors IX and X to the endothelial cell surface","volume":"111","author":"Heimark","year":"1983","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.blre.2018.01.001_bb0140","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2006.01401.x","article-title":"In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting","volume":"13","author":"Bjorkman","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2516.1997.00074.x","article-title":"The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications","volume":"3","author":"Bj\u00d6Rkman","year":"1997","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2010.02370.x","article-title":"Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia","volume":"17","author":"Collins","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0155","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1365-2516.2008.01806.x","article-title":"Obesity: a new disaster for haemophilic patients? A nationwide survey","volume":"14","author":"Hofstede","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0160","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/01.CIR.56.4.605","article-title":"Prediction of the normal blood volume. Relation of blood volume to body habitus","volume":"56","author":"Feldschuh","year":"1977","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2018.01.001_bb0165","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/jth.13242","article-title":"Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications","volume":"14","author":"Hazendonk","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.01.001_bb0170","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3324\/haematol.2015.136275","article-title":"A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients","volume":"101","author":"Hazendonk","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.01.001_bb0175","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2516.2009.02191.x","article-title":"Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A","volume":"16","author":"Bjorkman","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0180","first-page":"100","article-title":"In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients","volume":"22","author":"Preijers","year":"2016","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.blre.2018.01.001_bb0185","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/jth.13271","article-title":"Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization","volume":"14","author":"Brekkan","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.01.001_bb0190","series-title":"NONMEM users guide. NONMEM project group","first-page":"1","author":"Boeckmann","year":"2011"},{"key":"10.1016\/j.blre.2018.01.001_bb0195","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1365-2141.2000.02226.x","article-title":"Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery","volume":"110","author":"Batorova","year":"2000","journal-title":"Br J Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2018.01.001_bb0200","first-page":"P0829","article-title":"Surgeries in patients with haemophilia A performed with a continuous infusion of Recombinate","author":"N\u00e9grier","year":"2001","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.01.001_bb0205","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2516.2004.01013.x","article-title":"Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience","volume":"10","author":"Stieltjes","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0210","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2016-01-689869","article-title":"Platelet VIII pack evades immune detection","volume":"127","author":"Ragni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.01.001_bb0215","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1046\/j.1365-2516.2003.00721.x","article-title":"Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B","volume":"9","author":"Hoots","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1477-9560-5-14","article-title":"Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications","volume":"5","author":"Franchini","year":"2007","journal-title":"Thromb J"},{"key":"10.1016\/j.blre.2018.01.001_bb0225","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"Witmer","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2018.01.001_bb0230","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/hae.12592","article-title":"Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A","volume":"21","author":"Kepa","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0235","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","article-title":"Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight","volume":"119","author":"Bjorkman","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.01.001_bb0240","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/hae.12185","article-title":"Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals","volume":"19","author":"Kahlon","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0245","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1538-7836.2010.03753.x","article-title":"Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza","volume":"8","author":"Gezsi","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.01.001_bb0250","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/CIRCULATIONAHA.109.869156","article-title":"Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium","volume":"121","author":"Smith","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2018.01.001_bb0255","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2141.2004.05275.x","article-title":"Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort","volume":"128","author":"Morange","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.01.001_bb0260","series-title":"Onderzoek naar de toegankelijkheid en betaalbaarheid van geneesmiddelen in de medisch specialistische zorg","first-page":"1","author":"Nederlandse Zorgautoriteit","year":"2015"},{"key":"10.1016\/j.blre.2018.01.001_bb0265","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1160\/TH14-11-0925","article-title":"The \u201cOPTI-CLOT\u201d trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A","volume":"114","author":"Hazendonk","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.01.001_bb0270","series-title":"Handleiding voor kostenonderzoek: methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg","first-page":"1","author":"Hakkaart-van Roijen","year":"2010"},{"key":"10.1016\/j.blre.2018.01.001_bb0275","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1365-2516.1998.00161.x","article-title":"Low-dose intermittent factor replacement for post-operative haemostasis in haemophilia","volume":"4","author":"Srivastava","year":"1998","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0280","series-title":"Guideline for the management of patients with haemophilia undergoing surgical procedures","first-page":"1","author":"Australian Haemophilia Centre Directors' Organisation","year":"2010"},{"key":"10.1016\/j.blre.2018.01.001_bb0285","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2516.2008.01950.x","article-title":"Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations","volume":"15","author":"Hermans","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0290","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2516.2012.02879.x","article-title":"Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy","volume":"18","author":"Lindvall","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0295","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/hae.12905","article-title":"Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis","volume":"22","author":"Valentino","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0300","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2012.12727","article-title":"Association between physical activity and risk of bleeding in children with hemophilia","volume":"308","author":"Broderick","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2018.01.001_bb0305","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1111\/hae.13019","article-title":"Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A","volume":"22","author":"Fischer","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0310","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/hae.12463","article-title":"Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the VERITAS-Pro scale","volume":"20","author":"Lock","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0315","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/hae.12851","article-title":"Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment","volume":"22","author":"Lock","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0320","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13013","article-title":"The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO","volume":"22","author":"Collins","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.01.001_bb0325","series-title":"myPKFiT user guide","year":"2014"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16301047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16301047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T21:39:59Z","timestamp":1719783599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X16301047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0268960X16301047"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2018.01.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2018.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}